Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 13, 2007 Brian Lawler	Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool July 2, 2008 Brian Lawler	DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development.
The Motley Fool February 28, 2007 Brian Lawler	Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007.
The Motley Fool February 25, 2008 Brian Lawler	The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness.
The Motley Fool February 26, 2007 Brian Lawler	Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways.
The Motley Fool August 3, 2007 Brian Lawler	Endo Adjusting to Bigger Hopes The pharma announces its second-quarter financial results. As worries recede about near-term generic competition for lead drug Lidoderm, expectations for Endo have grown.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool April 30, 2007 Brian Lawler	Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note.
The Motley Fool January 22, 2007 Brian Lawler	The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned.
The Motley Fool February 22, 2007 Tom Taulli	Guidance's Legal "Land Grab" A major change in legal requirements should be a big boost for growth at Guidance Software. Investors, take note.
BusinessWeek December 11, 2006 Michael Arndt	When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch.
IndustryWeek June 1, 2005 John S. McClenahen	Financials -- Guiding Less The percentage of companies providing earnings guidance is declining.
The Motley Fool October 23, 2006 Brian Lawler	Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note.
The Motley Fool January 9, 2009 Alyce Lomax	Blue Christmas at Best Buy Best Buy narrows its fiscal 2009 guidance after disappointing holiday sales numbers proved it was not immune to the retail trend of abysmal December sales.
The Motley Fool October 12, 2010 Travis Hoium	King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool March 29, 2011 Anders Bylund	Setting the Stage for the Software Season Progress Software didn't give tech investors any reason to panic -- or to celebrate -- with their first quarter report.
CFO May 1, 2007 Joseph McCafferty	The Long View Corporate managers have long complained about the pressure to focus on the short term, but now, for the first time, critics and business groups are racing to their defense. The cure for the myopia? Stop giving quarterly earnings guidance.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool July 24, 2008 Brian Orelli	UnitedHealth Looking Healthier UnitedHealth Group isn't quite as sick as it appeared earlier this month, when it slashed yearly guidance by as much as $0.60 per share.
HBS Working Knowledge February 27, 2006 Jim Heskett	Summing Up: Should CEOs of Public Companies Offer Earnings Guidance? Readers weigh in: Anyone who has stock or investments in a public company should be privileged to certain short-term information... Employees feel pressure to have the business look good on a quarterly basis... etc.
InternetNews October 14, 2004 Paul Shread	Juniper Investors Turn Picky Juniper Networks beat estimates and raised guidance after the close on Thursday... Stocks fell sharply during the day on a GM earnings miss... The Nasdaq lost 17 to 1903... etc.
The Motley Fool September 29, 2006 Brian Lawler	Alpharma's Painless Results A new addition to an already successful drug promises good results for investors.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
The Motley Fool February 23, 2011 Cindy Johnson	Fear of the Future Outweighs HP's Great Quarter Did this tech titan's stock deserve to get slammed?
The Motley Fool December 15, 2006 Tom Taulli	Guidance Software: A Lawsuit's Best Friend This software company has found a strong growth channel. While Guidance is definitely solid, it may be worth waiting for the valuation to settle down.
HBS Working Knowledge February 13, 2006	Readers Respond: Should CEOs of Public Companies Offer Earnings Guidance? Business professional offer opinions on the question of whether CEOs of public companies offer earnings guidance.
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
InternetNews April 3, 2007 Roy Mark	FTC Approves Final Guidance Settlement Guidance Software's settlement with the Federal Trade Commission became official today, almost five months after the Pasadena, Calif.-based computer forensics specialist admitted it did not adequately protect customer data.
The Motley Fool June 27, 2005 Nathan Slaughter	Ignore Earnings Guidance Instead of searching for companies that merely sound optimistic, seek out those willing to back up that positive outlook with something more substantive than words, like dividend increases.
BusinessWeek August 9, 2004 Gene G. Marcial	MGI Pharma Has Just What Patients Need Its first major drug, an injection to prevent chemotherapy-induced nausea and vomiting, is on fire in a $1.5 billion market. And turning MGI into a moneymaker.
InternetNews November 16, 2006 Roy Mark	Guidance Software Settles With FTC Guidance Software agreed Thursday to settle Federal Trade Commission charges that the computer forensics specialist did not take reasonable security measures to protect sensitive customer data.
Entrepreneur August 2005 C.J. Prince	Just Say No? More big companies are refusing to give Wall Street quarterly earnings guidance. Should small firms jump on the bandwagon, too? Observers comment on longer term vs shorter term perspective.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.